Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD

Exclusion Criteria

• •Current Colchicine therapy
• •Hepatic disease
• •Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
• •Immunosuppression
• •Current use of chemotherapy drugs or active cancer
• •Pregnancy/breastfeeding
• •Hospitalized within the past 6 months
• •Allergic/intolerance to colchicine
• •Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
• •Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
• •Human immunodeficiency virus (HIV) infection
• •Gout attack ≥ 1 time per year
• •Severe anemia (hemoglobin \< 8 g/dl for women and \< 9 g/dl for men)
• •eGFR \<30 ml/min/1.73m2
• •uACR \<200 mg/g
• •White blood cell count (WBC) \<3.0 x109/L
• •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 x Upper Limit of Normal (ULN)
• •Total bilirubin \>2 x ULN
• •Glucose \>300mg/dl
• •Uses nicotine products or other recreational drugs
• •Unable to read or speak English
• •Participant in other conflict clinical trial,
• •Unable to complete the study measurements
• •Unable to undergo to computed tomography (CT) or dual-energy X-ray absorptiometry (DXA) scans
• •Unsafe to participate in this study per investigator's judgement.